Ibrutinib
Pronunciation: eye-BROO-ti-nib
A Bruton's tyrosine kinase (BTK) inhibitor used primarily in B-cell malignancies including CLL and mantle cell lymphoma.
Full Definition
Ibrutinib is an oral targeted therapy that irreversibly inhibits Bruton's tyrosine kinase, a crucial protein in B-cell receptor signaling pathways. It has revolutionized treatment for chronic lymphocytic leukemia, mantle cell lymphoma, and other B-cell malignancies by blocking proliferation and survival signals in malignant B cells. The drug is administered continuously until disease progression or unacceptable toxicity. Notable side effects include bleeding risk, atrial fibrillation, and hypertension, requiring careful monitoring during treatment.
Usage
Usage note: Distinguish from other kinase inhibitors; specify mechanism of action when discussing with non-hematology colleagues.
In Context
- "The patient achieved a partial response after six months of ibrutinib monotherapy for relapsed CLL." — Response assessment report
- "Ibrutinib was held for 48 hours prior to the surgical procedure due to bleeding risk." — Perioperative care note